<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04595045</url>
  </required_header>
  <id_info>
    <org_study_id>LINITOX</org_study_id>
    <nct_id>NCT04595045</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin in Patients With Spastic Lower Limb Paresis Associated With Multiple Sclerosis</brief_title>
  <official_title>Effectiveness of Botulinum Toxin Type A Infiltrations in the Gait and Quality of Life in Adults With Spastic Lower Limb Paresis Secondary to Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aránzazu Vázquez Doce</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spastic paraparesis is one of the most disabling functional deficits in the population with&#xD;
      multiple sclerosis between 18 and 80 years of age and at any functional level. Infiltration&#xD;
      with Botulinum Toxin is a clinical practice that has been carried out for years with clinical&#xD;
      evidence of improvement in the patient's walking patterns and quality of life. We assume that&#xD;
      the infiltration of this product can generate a direct benefit in the walking ability of&#xD;
      these patients and secondarily improve their quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of repeated Botulinum Toxin infiltrations using objective results obtained by the clinician (Six Minutes Walking Test - 6MWT).</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the effectiveness of repeated Botulinum Toxin infiltrations on gait in patients with Multiple Sclerosis who presented limb spasticity less than 4 weeks after infiltration and its maintenance over time at 12 months, using objective results obtained by the clinician (Six Minutes Walking Test - 6MWT). Higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of repeated Botulinum Toxin infiltrations using results reported by the patient (Twelve item Multiple Sclerosis Walking Scale - MSWS-12).</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the effectiveness of repeated Botulinum Toxin infiltrations on gait in patients with Multiple Sclerosis who presented limb spasticity less than 4 weeks after infiltration and its maintenance over time at 12 months, using results reported by the patient (Twelve item Multiple Sclerosis Walking Scale - MSWS-12). Higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of spasticity using Modified Ashworth Spasticity scale (MAS scale).</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of spasticity using Modified Ashworth Spasticity scale (MAS scale). Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disability using Expanded Disability Status Scale de Kurtzke (EDSS scale).</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of disability using Expanded Disability Status Scale de Kurtzke (EDSS scale). Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the quality of life after the use of botulinum toxin type A using Multiple Sclerosis Quality of Life 54 (MSQoL-54).</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of the quality of life after the use of botulinum toxin type A using Multiple Sclerosis Quality of Life 54 (MSQoL-54). Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of medium and long-term objectives using Goal Attainment Scaling (GAS scale).</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of medium and long-term objectives using Goal Attainment Scaling (GAS scale). Higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events.</measure>
    <time_frame>12 months</time_frame>
    <description>Number of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>patients with spastic lower limb paresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with spastic lower limb paresis secondary to Multiple Sclerosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A infiltrations</intervention_name>
    <description>Echo-guided infiltration of botulinum toxin type A (Dysport®) in the lower limbs according to normal service practice</description>
    <arm_group_label>patients with spastic lower limb paresis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acceptance and signature of informed consent.&#xD;
&#xD;
          -  Age between 18 and 80 years old, both included.&#xD;
&#xD;
          -  Patients with relapsing remitting multiple sclerosis (RRMS), progressive secondary&#xD;
             (SP) and primary progressive (PP), with spasticity resistant to usual treatment,&#xD;
             either because of the severity of the spasticity or because of intolerance to side&#xD;
             effects.&#xD;
&#xD;
          -  Outpatients with spastic paraparesis that causes gait deficiency.&#xD;
&#xD;
          -  Patients with an EDSS score between 2 and 6, both included.&#xD;
&#xD;
          -  Patients with segmental involvement in MAS &gt;1 in two or more muscle groups in the&#xD;
             lower extremities.&#xD;
&#xD;
          -  Absence of cognitive disability. Score less than 5 on the SPMSQ scale of Pfeiffer.&#xD;
&#xD;
          -  Possibility of carrying out the treatment (method of administration, scheduled visits)&#xD;
             and scales correctly.&#xD;
&#xD;
          -  Women of childbearing potential should use an effective contraceptive method (hormonal&#xD;
             contraceptives, intrauterine device, condom) or refrain from having sex in order not&#xD;
             to get pregnant. A woman is considered to be fertile after menarche and to become&#xD;
             postmenopausal, unless she has undergone a permanent sterilization procedure&#xD;
             (hysterectomy, salpingectomy, bilateral oophorectomy). A postmenopausal state is&#xD;
             defined as absence of menstruation for 12 months without an alternative medical cause.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric illness that hinders participation in the trial.&#xD;
&#xD;
          -  Comorbidity that threatens the patient's life in the short term (severe liver disease,&#xD;
             cardiovascular disease, etc.).&#xD;
&#xD;
          -  Osteoarticular disorder that prevents physical activity.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Lack of primary or secondary response to any type of Botulinum Toxin for the treatment&#xD;
             of MS previously detected.&#xD;
&#xD;
          -  Sensitivity to Botulinum Toxin or to any excipient.&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, may compromise&#xD;
             compliance with the objectives and / or procedures of this protocol or preclude the&#xD;
             administration of Botulinum Toxin.&#xD;
&#xD;
          -  Changes in the treatment regimen of any drug that directly or indirectly interferes&#xD;
             with neuromuscular function within 4 weeks before the start of the study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Aránzazu Vázquez Doce</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Botulinum toxin type A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

